Cantor Fitzgerald raised the price target for the CymaBay Therapeutics Inc. (NASDAQ:CBAY) stock to “an Overweight”. The rating was released on April 11, 2022, according to finviz. We previously noted in another research note published on August 04, 2020 by H.C. Wainwright that reiterated the stock to a Buy with a price target of $13 for CBAY stock. The research report from Piper Sandler has initiated the stock to Overweight, with a price target set at $12. The stock was upgraded by H.C. Wainwright, who disclosed in a research note on May 26, 2020, from Neutral to Buy and set the price objective to $9. In their research brief published May 12, 2020, SVB Leerink analysts upgraded the CymaBay Therapeutics Inc. stock from Mkt Perform to Outperform with a price target of $6.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of CymaBay Therapeutics Inc. (NASDAQ:CBAY) raised 15.89% to close Tuesday’s market session at $7.66, higher as compared to yesterday’s close. The stock price fluctuated between $7.02 and $7.825 throughout the trading session with the volume trading being 6777679 shares, which represented a significant variation when compared to the three months average volume of 764.63K shares. The firm’s stock price fluctuated 12.81% within the last five trades and 54.44% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 143.95% in the last 6 months and 132.12% was added to its value over the previous 3 months. CBAY stock is trading at a margin of 25.35%, 62.12% and 120.16% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, CBAY deals in the Healthcare domain. The stock is trading 7.15 percent below its 52-week high and 358.66 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 135.45. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does CymaBay Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $624.37 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 11.10, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.39 percent of CymaBay Therapeutics Inc. shares are owned by insiders, and 76.30 percent are held by financial institutions. Shah Sujal, the Chief Executive Officer at CymaBay Therapeutics Inc. (CBAY) has bought 51,301 shares of firm on Jun 06 at a price of $1.95 against the total amount of $0.1 million.